FDA approves Zeposia to treat relapsing forms of multiple sclerosis ,including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.-BMS
Bristol-Myers Squibb Company announced that the FDA approved Zeposia (ozanimod) 0.92 mg for the treatment of adults with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome,… read more.